Myeloma Paper of the Day, October 7th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Italian multicenter real-life observational retrospective study of Isatuximab-Kd for RRMM finds ORR 85%, sCR or CR 18%, VGPR 39%, 1-year PFS and OS of 72% and 77%, with hematologic toxicities in 42% and cardiac toxicities in 24%.”

Source: Robert Orlowski/X

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Authors: Danilo De Novellis, Daniele Derudas, Donatella Vincelli, Raffaele Fontana, Roberta Della Pepa, Salvatore Palmieri, Fabrizio Accardi, Francesco Rotondo, Emanuela Morelli, Emilia Gigliotta, Daniela Roccotelli, Luana Marano, Maria Lucia Barone, Giusy Cetani, Daniela Esposito, Antonio Lazzaro, Giuseppe Delle Cave, Bianca Serio, Denise Morini, Marika Porrazzo, Eleonora Urciuoli, Chiara Masucci, Fulvia Fanelli, Michela Rizzo, Manuela Arcamone, Fabio Trastulli, Stefano Rocco, Aldo Leone, Rosario Bianco, Flavia Salvatore, Aurora Idato, Maria Sicari, Patrizia Tosi, Maria Gabriella Rascato, Maria Di Perna, Antonietta Pia Falcone, Lucia Morello, Melania Carlisi, Gino Svanera, Mario Annunziata, Ferdinando Frigeri, Catello Califano, Angelo Michele Carella, Gianpaolo Marcacci, Fabrizio Pane, Antonio Maria Risitano, Valentina Giudice, Ciro Botta, Carmine Selleri.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.